financetom
Business
financetom
/
Business
/
Ibotta Q3 Adjusted Earnings, Revenue Increase; Q4 Guidance Set
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ibotta Q3 Adjusted Earnings, Revenue Increase; Q4 Guidance Set
Nov 13, 2024 1:42 PM

04:23 PM EST, 11/13/2024 (MT Newswires) -- Ibotta ( IBTA ) reported Q3 adjusted earnings late Wednesday of $0.94 per diluted share, up from $0.71 a year earlier.

Two analysts polled by Capital IQ expected $0.69.

Revenue for the quarter ended Sept. 30 rose to $98.6 million from $85.3 million a year earlier.

Analysts surveyed by Capital IQ expected $94.1 million.

The company said it expects Q4 revenue of $100 million to $106 million. Analysts polled by Capital IQ expect $110.3 million.

Shares of the company dropped past 15% in recent after-hours activity.

Price: 63.40, Change: -11.53, Percent Change: -15.39

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report
Oct 11, 2024
Perspective Therapeutics, Inc. ( CATX ) is down 13% at $11.53 at last check Friday. The downtrend comes as initial results from its study of [212Pb]VMT01 are set to be presented to the International Congress of the Society for Melanoma Research. VMT01 is a MC1R-targeted radiopharmaceutical therapy (RPT) that can be radiolabeled with either 203Pb for patient selection and dosimetry assessments or 212Pb...
US says FAA oversight of Boeing production 'not effective'
US says FAA oversight of Boeing production 'not effective'
Oct 11, 2024
* FAA's audit processes not comprehensive enough, says report * FAA agrees with 16 recommendations to improve oversight * FAA has not enforced timely resolution of undue pressure allegations By David Shepardson WASHINGTON, Oct 11 (Reuters) - A federal watchdog on Friday criticized the Federal Aviation Administration's oversight of Boeing ( BA ) airplane production, saying it does not have...
Eni CEO says U.S. funds are showing confidence in group's strategy
Eni CEO says U.S. funds are showing confidence in group's strategy
Oct 11, 2024
MILAN (Reuters) - U.S. investment funds are showing confidence in Eni's strategy of spinning off growth businesses in order to attract financial resources, the Italian energy group's CEO Claudio Descalzi said on Friday. Under its so-called 'satellite' strategy, Eni has created several companies dedicated to low-carbon businesses and upstream assets and is currently in talks with U.S. fund KKR to...
Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years
Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years
Oct 11, 2024
On Friday, Capricor Therapeutics ( CAPR ) announced 3-year safety and efficacy results from its ongoing HOPE-2 open-label extension (OLE) study for its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disease that causes progressive muscle weakness and degeneration.  Cardiac and orthopedic complications, including scoliosis and contractures (tightened muscles)  The data was highlighted at...
Copyright 2023-2025 - www.financetom.com All Rights Reserved